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Abstract
Heat shock protein 47 (HSP47), encoded by the SERPINH1 gene, is a molecular chaperone
essential for correct folding of collagens. We report a homozygous p.(R222S) substitution in
HSP47 in a child with severe osteogenesis imperfecta leading to early demise. p.R222 is a
highly conserved residue located within the collagen interacting surface of HSP47. Binding
assays show a significantly reduced affinity of HSP47-R222S for type I collagen. This altered
interaction leads to posttranslational overmodification of type I procollagen produced by der-
mal fibroblasts, with increased glycosylation and/or hydroxylation of lysine and proline resi-
dues as shown by mass spectrometry. Since we also observed a normal intracellular folding
and secretion rate of type I procollagen, this overmodification cannot be explained by pro-
longed exposure of the procollagen molecules to the modifying hydroxyl- and glycosyltrans-
ferases, as is commonly observed in other types of OI. We found significant upregulation of
several molecular chaperones and enzymes involved in procollagen modification and folding
on Western blot and RT-qPCR. In addition, we showed that an imbalance in binding of
HSP47-R222S to unfolded type I collagen chains in a gelatin sepharose pulldown assay
results in increased binding of other chaperones and modifying enzymes. The elevated
expression and binding of this molecular ensemble to type I procollagen suggests a compen-
satory mechanism for the aberrant binding of HSP47-R222S, eventually leading to overmodi-
fication of type I procollagen chains. Together, these results illustrate the importance of
HSP47 for proper posttranslational modification and provide insights into the molecular patho-
mechanisms of the p.(R222S) alteration in HSP47, which leads to a severe OI phenotype.
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Author summary
Heat shock protein 47 (HSP47) is essential for correct collagen folding. We report a
homozygous p.(R222S) substitution in HSP47 in a child with severe osteogenesis imper-
fecta. The highly conserved p.R222 residue is located within the collagen interacting sur-
face and HSP47-R222S shows a significantly reduced affinity for type I collagen. This
altered interaction leads to posttranslational overmodification of type I procollagen. In
contrast to other types of OI, this overmodification is not caused by prolonged exposure
of procollagen to modifying enzymes, since the intracellular folding rate of type I procolla-
gen appears to be normal. We show significant upregulation of several molecular chaper-
ones and collagen-modifying enzymes and increased binding of several of these molecules
to unfolded type I collagen chains upon abnormal HSP47-R222S binding. This suggests a
compensatory mechanism for aberrant HSP47-R222S binding, eventually leading to over-
modification of type I procollagen chains, and underscores the importance of HSP47 for
proper posttranslational modification.
Introduction
Type I collagen is the most abundant extracellular matrix protein in humans and plays critical
roles in many connective tissues such as bone, tendon and skin. The biosynthesis of type I col-
lagen is a particularly complex process, which starts with the synthesis of precursor procollagen
chains (pro-α1(I)-chains encoded by COL1A1 and pro-α2(I)-chains encoded by COL1A2).
These precursor chains typically consist of a long helical domain, which contains multiple Gly-
Xaa-Yaa repeats, flanked by globular carboxy- (C-) and amino- (N-) terminal domains. In the
rough endoplasmic reticulum (rER) two pro-α1(I)-chains and one pro-α2(I)-chain associate at
their C-propeptide and fold into an elongated triple helix, which propagates in a zipper-like
fashion towards the N-terminus. Prior to this helix formation several posttranslational modifi-
cations occur, including prolyl 4-hydroxylation, prolyl 3-hydroxylation and lysyl hydroxyl-
ation. Galactose or glucosyl-galactose sugars are additionally attached to some of the hydroxyl-
lysine residues. The enzymes responsible for these modifications can only act on non-triple
helical pro-α-chains, and posttranslational modifications cease once triple helix formation is
completed. [1] Correct folding, modification and secretion of the procollagen chains requires
the concerted action of over 20 rER-resident molecules including chaperones, enzymes and
posttranslational modifiers, collectively coined as the ‘molecular ensemble’. [2] One of these
molecules is the molecular chaperone HSP47, which is encoded by the SERPINH1 gene.
HSP47 was discovered in the late 1980s as a 47-kDa collagen-binding and heat shock protein.
[3] HSP47 specifically binds to procollagens and has a characteristic expression pattern in cells
and tissues that closely correlates with that of collagens. [4,5] It preferentially binds the folded
triple helix [6], recognizing Gly-Xaa-Arg triplets across the helix. [7] The elucidation of the
HSP47 crystal structure revealed that two HSP47 molecules bind to two of the three α-chains
of homotrimeric synthetic collagen model peptides. [8] As such, HSP47 molecules stabilize the
triple helix structure during folding and also prevent lateral association of procollagen triple
helices in the ER. [9,10] Furthermore, HSP47 acts as an anchor molecule between procollagens
and the SH3 domain of TANGO1, a membrane sorting receptor that is present at ER exit sites
and that ensures efficient sorting into and enlarging of special procollagen transport vesicles.
[11] It has been suggested that HSP47 also accompanies folded procollagen molecules to the
cis-Golgi or the ER-Golgi intermediate compartment (ERGIC) in large COPII carriers. [12] In
the Golgi apparatus, the pH drop releases HSP47 from procollagen, which is then shuttled
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back to the ER by its C-terminal RDEL sequence. [13] The importance of HSP47 during devel-
opment is illustrated by the embryonic lethality of Serpinh1 knockout mice, which do not sur-
vive beyond 11.5 days postcoitus (dpc). Genetic ablation of Hsp47 results in virtual absence of
collagen fibers and disrupted basement membranes in these mouse embryos, which also dis-
play abnormally oriented epithelial tissues and ruptured blood vessels. [14] Pathogenic variants
in the SERPINH1 gene (OMIM 600943) cause osteogenesis imperfecta (OI, OMIM 613848) in
humans and dogs. The first evidence for the involvement of defective HSP47 in OI came from
rough-coated Dachshunds displaying a severe OI phenotype, who were found to harbor a
homozygous SERPINH1 p.(Leu326Pro) variant. [15] In 2010, a homozygous substitution
(p.(Leu78Pro)) in HSP47 was described in a young child with severe OI. [16] Subsequently, bi-
allelic SERPINH1 variants were described in seven additional individuals from five unrelated
families, suffering from moderately severe to neonatal lethal OI. [17–21] These variants
included homozygous or compound heterozygous missense variants (p.(Met237Thr) [17] and
p.[(Leu50Arg)];[(Arg405His)] [20]), a homozygous in-frame deletion (p.(Glu105_His108del))
[18], a homozygous frameshift variant (p.(Glu113Valfs�8)) [19], and a compound heterozy-
gous nonsense variant (p.(Asp412�) combined with a >5 kb genomic deletion located 2.37 kb
upstream of the transcription start site. [21]
Here, we report the ninth patient suffering from severe OI caused by a novel homozygous
SERPINH1 missense variant (p.(R222S)). We performed in depth characterization of the effect




The patient is the only child of non-consanguineous, healthy Indian parents. At birth she
presented with blue sclerae, a large anterior and posterior fontanel, bilateral bowing of the
femur and multiple fractures. A skeletal survey at 4 days of age confirmed fractures with cal-
lus formation in both femora, gracile and thin ribs with fractures, platyspondyly and general-
ized severe hypomineralisation (Fig 1A–1C). Skull X-rays showed severe thinning and
Wormian bones (Fig 1D). Intravenous administration of pamidronate was started at the age
of 16 days and administered every two months. At the age of 2.5 years she underwent Shef-
field telescoping rod insertion for both femurs, after which she started to walk with support.
Facial features at this age included a triangular face with relative macrocephaly, a prominent
forehead, blue sclerae, micrognatia and dentinogenesis imperfecta. Cardiac examination was
unremarkable. Otoacoustic emission test failed bilaterally. At 38 months, her height was 76.5
cm (<1st percentile), weight was 7.8 kg (<1st percentile) and head circumference was 49 cm
(>1st percentile). She had a large anterior fontanel, short neck, scoliosis and severe crowding
of ribs. X-rays showed good mineralization with ‘Zebra lines’ following regular pamidronate
infusions (Fig 1E and 1F). Because the fracture rate was extremely low, the family decided to
discontinue pamidronate infusions. At age 4.5 years, she died from pneumonia. No autopsy
was performed.
Clinical data of this patient and all reported patients with pathogenic SERPINH1 variants is
summarized in S1 Table.
Identification of a novel homozygous SERPINH1 variant
After excluding defects in COL1A1 and COL1A2, molecular analysis was performed for all
other known genes associated with OI. This revealed a homozygous c.664C>A transversion
in the SERPINH1 gene, resulting in the substitution of a highly conserved amino acid
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Fig 1. Radiological features. (A-C) X-rays at age 4 days (A), 2 months (B) and 8 months (C) show fractures with
callus formation, gracile and thin ribs with fractures, platyspondyly and severe hypomineralization. (D) Skull X-ray at
age 10 months shows severe thinning and Wormian bones. (E-F) X-rays at 3 years of age show crowding of the ribs,
scoliosis and femora with ‘Zebra lines’ following regular pamidronate infusions.
https://doi.org/10.1371/journal.pgen.1009339.g001
PLOS GENETICS HSP47 mutation leads to osteogenesis imperfecta
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009339 February 1, 2021 4 / 27
(p.(Arg222Ser) or p.(R222S)) (Fig 2A and 2B). The variant was reported only once in heterozy-
gous state in public databases (1 in 251,474 alleles, queried on November 8, 2020) and the
majority (3/4) of in silico prediction algorithms considered it to have deleterious effects (S2
Table). According to the guidelines of the American College of Medical Genetics and Geno-
mics, the variant was classified as likely pathogenic (class 4). Segregation analysis revealed
that both healthy parents are heterozygous carriers of this variant (Fig 2A). Quantitative
reverse transcription (RT-qPCR) showed normal SERPINH1 mRNA expression in fibroblast
cultures derived from the proband, compared to control (Fig 2C). No apparent differences in
HSP47 protein levels (Figs 2D and 5) and subcellular localization (Fig 2F) were observed by
Western blot and immunofluorescence analysis on dermal fibroblast cultures, indicating that
HSP47-R222S protein is stably produced and correctly localized to the ER.
HSP47-R222S has reduced binding capacity for type I collagen
Mapping of the substitution on the canine HSP47 crystal structure, which shows 97% sequence
identity to the human HSP47, revealed that the affected p.R222 residue is located within the
collagen interacting surface of HSP47, suggesting a crucial role for this residue in binding of
HSP47 to type I collagen (Fig 3A–3D). [8]
In order to test whether this substitution affected binding of HSP47 to type I collagen,
recombinant wild-type and R222S canine HSP47 were produced in Escherichia coli. Differen-
tial Scanning Fluorimetry showed a similar melting point for both wild-type (54.50˚C) and
R222S (54.00˚C) protein, confirming that the variant does not cause structural instability
(S1 Fig).
First, direct binding kinetics of wild-type and R222S HSP47 were analyzed for a collagen-
like GPR peptide (GPR-foldon) using Biolayer Interferometry (BLI) and full length pepsinized
type I collagen from mouse tail tendon using Surface Plasmon Resonance (SPR) analysis.
Wild-type HSP47 was shown to interact in a concentration dependent manner with both
immobilized GPR-foldon (Fig 3F) and immobilized type I collagen (Fig 3G). Although
HSP47-R222S also showed a concentration-dependent interaction, its ability to bind to the
GPR-foldon or type I collagen was markedly reduced, even with higher concentrations of
HSP47-R222S protein (Fig 3F and 3G). The equilibrium dissociation constant (KD) for wild-
type (0.409 ± 0.004 μM) and R222S (11.479 ± 0.154 μM) HSP47 revealed an approximately
25-fold lower affinity of HSP47-R222S for the GPR-foldon with BLI (Fig 3F), while KD
values determined by SPR showed a ~10-fold weaker binding affinity of HSP47-R222S
(0.64 ± 0.08 μM) to type I collagen compared to wild-type HSP47 (0.06 ± 0.006 μM) (Fig 3G).
While the dissociation rate constant (koff) was relatively similar between wild-type and R222S
HSP47 in both BLI and SPR, the association rate constant (kon) was altered, suggesting that
HSP47-R222S also shows a slower association with the GPR-foldon (Fig 3F) and type I colla-
gen (Fig 3G).
These findings were subsequently confirmed using an enzyme-linked immunosorbent
binding assay (ELISA-like binding assay). Analysis of wild-type HSP47 showed a slightly
higher affinity for type I collagen compared to GPR-foldon, with KD values of 139 nM and 56
nM, respectively. For HSP47-R222S a shift in the curves was seen, confirming that the binding
of HSP47-R222S to both the GPR-foldon and to full length type I collagen was severely
reduced compared to wild-type HSP47. This is reflected by KD values of approximately 1.5 μM
(GPR-foldon) and 3.6 μM (type I collagen), which were roughly 25 times worse than for the
wild-type HSP47 protein (Fig 3E).
Collectively, these results demonstrate that the affinity of HSP47-R222S for the collagen tri-
ple helix is severely reduced, though not completely abolished, in comparison with wild-type
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Fig 2. Variant identification and characterization. (A) Electropherograms of the identified variant in the patient, unaffected
parents and control. WT: wild-type, M: mutant. (B) Protein sequence alignment of different species. The affected p.Arg222 residue
is shaded in grey. (C) RT-qPCR expression analysis for SERPINH1. Data are expressed as mean ± SEM. (D) Western blot analysis
for HSP47. (E) HSP47 domain structure with inclusion of all pathogenic variants identified to date. The variant reported here is
depicted above the structure. Numbers above the structure indicate amino acid residues. The pathogenic variant with a hashtag (#)
depicts the only canine variant identified so far. The reported upstream genomic deletion is not depicted in this image. SP: signal
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HSP47. As such, these findings confirm a significant role of the p.R222 residue for binding of
HSP47 to type I collagen.
HSP47-R222S alters synthesis and stability of type I collagen
Next, the consequences of the p.(R222S) substitution on HSP47 chaperone functionality and
its effects on the biosynthesis and properties of type I (pro)collagen were evaluated. To this
end, biochemical analysis of metabolically labeled (pro)collagen chains was performed.
peptide. (F) Immunocytochemical analysis showing colocalization of wild-type and R222S HSP47 with the ER-marker PDI. Nuclei
are counterstained with DAPI. Scale bar = 50 μm. C: control and P: patient.
https://doi.org/10.1371/journal.pgen.1009339.g002
Fig 3. Determination of the binding properties of WT and R222S HSP47. (A-D) Crystal structure of the HSP47-collagen interaction with the collagen trimer
depicted centrally, surrounded by two HSP47 molecules depicted in light and dark grey. (A,C) Wild-type (WT) and (B,D) R222S HSP47. (E) ELISA binding assay of
wild-type (WT) and R222S HSP47 to GPR-foldon and type I collagen from rat tail. (F-G) Concentration dependent direct binding of WT and R222S HSP47 proteins
with (F) GPR-foldon using biolayer interferometry and (G) type I collagen using surface plasmon resonance. All curves are averaged by a minimum of three
measurements. Tables represent the respective binding affinities. Results are shown as mean ± SD.
https://doi.org/10.1371/journal.pgen.1009339.g003
PLOS GENETICS HSP47 mutation leads to osteogenesis imperfecta
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009339 February 1, 2021 7 / 27
Steady-state analysis of pepsinized collagen separated by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) showed that the bands representing the type I collagen
α-chains showed a decreased electrophoretic mobility in both medium and cell layers of
patient fibroblasts compared to control fibroblasts (Fig 4A). These findings are suggestive for
posttranslational overmodification of the type I collagen α-chains.
Since HSP47 is required for correct folding of type I procollagen [9], the effect of the p.
(R222S) substitution on the folding rate, secretion rate and stability of type I collagen was
Fig 4. Consequences for type I (pro)collagen synthesis, thermal stability, intracellular folding and secretion. (A) Steady-
state biochemical (pro)collagen analysis of (pro)collagens harvested from medium and cell layer from dermal fibroblast
cultures. (B) Intracellular folding assay for type I collagen measured by pulse-chase labeling of type I collagen with AHA-Alexa
Fluor 488 and staining of the total amount of type I collagen (with and without AHA) with GelCode Blue Stain Reagent. ‘-‘
denotes Alexa Fluor 488 labeled TBS buffer only, Ctrl: purified AHA incorporated type I collagen from culture medium after
overnight chase as a loading control. (C) Type I collagen secretion assay. (D) Thermal stability of secreted type I collagen
molecules with biochemical analysis. (E) Melting curve analysis of type I collagen measured in the control (black) and patient
(pink) by circular dichroism measurements. C: control, P: patient.
https://doi.org/10.1371/journal.pgen.1009339.g004
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investigated. A normal intracellular folding (Figs 4B and S2) and secretion rate (Figs 4C and
S3) of type I procollagen was detected. In addition, a slightly increased thermal stability of type
I collagen α-chains (Fig 4D) was observed in patients’ fibroblast cells compared to control,
which is most likely a consequence of overmodification. This was confirmed using circular
dichroism (CD) measurements, which showed a slight shift to higher temperatures in the melt-
ing curve of type I collagen in the patient sample compared to control both at a heating rate of
0.1˚C/min (Fig 4E) and 1˚C/min (S4 Fig).
Overall, these findings show that the reduced binding of HSP47-R222S to type I procollagen
chains is associated with type I (pro)collagen overmodification, which leads to a mildly
increased thermal stability. Despite the observed overmodification, folding and secretion of
type I collagen was normal.
HSP47-R222S increases posttranslational modification of type I collagen
In order to quantitate and characterize the posttranslational modifications of type I collagen,
amino acid analysis and mass spectrometry was performed to determine the modification on
selected residues in the triple helical region.
Overall, amino acid analysis revealed a significant increase in 3-hydroxylated proline and
4-hydroxylated proline levels, with an increase of 65% and 2.5%, respectively, in the patient
sample compared to control (S5A, S5D and S5E Fig). The relatively low increase in 4-hydrox-
ylated proline can be attributed to the fact that proline residues in the Yaa position are typically
almost fully 4-hydroxylated. Whereas mass spectrometry analysis showed that the A1 site
(Pro-986) of the α1(I)-collagen chain was almost completely 3-hydroxylated in both patient
and control dermal fibroblasts (S6A Fig), 3-hydroxylation for the A3 site (Pro-707) was
increased in patient compared to control (S6B Fig).
In addition, amino acid analysis demonstrated that type I collagen produced by patient cells
contained 60% more hydroxylysine moieties compared to control (S5B, S5D and S5E Fig).
This is substantially higher when compared to the initially reported patients with CRTAP and
LEPRE1 mutations, where an increase in hydroxylysines is seen ranging between 31.3–35.1%
and 32.4–35.3%, respectively. [22,23] Mass spectrometry confirmed that Lys-756 of the α1(I)-
chain showed a markedly increased amount of hydroxylysine in the patient sample compared
to control (S6E Fig). Hydroxylysine residues are important for crosslinking, but can also be
glycosylated. [24] Type I collagen from patient fibroblasts harbored about 50% more glucosyl-
galactosyl-hydroxylysines compared to control (S5C Fig). Lys-174 of the α1(I)-chain was
nearly completely modified to glucosyl-galactosyl-hydroxylysine in the patient (S6C Fig), and
increased amounts of galactosyl hydroxylysine and glucosyl-galactosyl-hydroxylysine were
also found at Lys-531 of the α1(I)-chain compared to control (S6D Fig). These results con-
firmed the overmodification of type I collagen seen on biochemical analysis (SDS-PAGE).
HSP47-R222S leads to upregulation of modifying enzymes and chaperones
as well as alternative composition of the molecular ensemble
In an attempt to explain the observed overmodification of type I collagen that was unexpect-
edly combined with normal folding, the protein and mRNA expression levels of various
enzymes and chaperones involved in procollagen biosynthesis were quantified by Western
blot and RT-qPCR analysis, respectively, in patient and control fibroblasts. Western blot analy-
sis indicated a significant upregulation for the majority of the evaluated proteins, including the
peptidyl-prolyl cis/trans isomerase (PPIase) FK506 binding protein 65kDa (FKBP65, encoded
by FKBP10) and cyclophilin B (CypB, encoded by PPIB); posttranslational modifiers, prolyl
3-hydroxylase 1 (P3H1, encoded by LEPRE1 (P3H1)), prolyl 3-hydroxylase 3 (P3H3, encoded
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by P3H3), prolyl 4-hydroxylase 1 (P4HA1, encoded by P4HA1), lysine hydroxylase 1 (LH1
encoded by PLOD1) and 3 (LH3, encoded by PLOD3); and posttranslational modifier binding
proteins protein disulfide isomerase (PDI, encoded by P4HB), cartilage associated protein
(CRTAP, encoded by CRTAP) and synaptonemal complex 65 (SC65 or P3H4, encoded by
P3H4). The levels of the telopeptide-specific lysine hydroxylase 2 (LH2, encoded by PLOD2)
and glycosyltransferase 25 domain-containing 1 (GLT25D1, encoded by COLGALT1) were
decreased, whereas HSP47-RSSS2 protein levels remained unaltered compared to control
(confirming our previous findings) (Figs 5 and S7).
To evaluate whether the increased protein levels resulted from upregulated gene expression,
RT-qPCR was performed to check the corresponding mRNA expression levels. For the genes
encoding proteins that were upregulated, expression analysis revealed either a significant
increase in transcript levels (FKBP10, PPIB, P3H1, P3H3, PLOD1, PLOD3 and P4HB) or a
trend towards increased expression (CRTAP, P4HA1 and P3H4). Expression levels of PLOD2
were not significantly different, but surprisingly, COLGALT1 was upregulated at transcrip-
tional level, despite decreased protein levels (S8 Fig).
We next performed a gelatin sepharose pulldown assay to evaluate binding of wild-type and
HSP47-R222S as well as the various biosynthetic enzymes and chaperones to denatured type I
collagen. Wild-type, but not R222S, HSP47 was able to interact with denatured collagen (Fig
6A, 6B and 6E). In contrast, CRTAP, CypB, P3H1, P3H3, P4HA1, LH1, PDI and BiP showed a
significantly increased binding to gelatin sepharose in the absence of HSP47 binding (Figs 6D
and S9A), with BiP demonstrating the highest increase compared to control fibroblasts (Fig
6C–6E), despite unaltered endogenous expression and protein levels (Figs 6C, S8 and S10A).
Binding to gelatin sepharose was not significantly increased for FKBP65 and no binding was
observed for GRP94 (HSP90), Calreticulin and LH3 (S9B Fig).
Fig 5. Comparison of protein levels of the molecular ensemble. Semi-quantitative Western blotting was performed
to see effects of the SERPINH1 variant on actual protein levels of the molecular ensemble involved in collagen
biosynthesis. The protein signals were normalized to β-tubulin levels and each value was set to 1 for the control. Data
presented are means ± SEM and individual data points represent independently prepared cell lysates (n>10). �:
p<0.05, ��: p<0.01 and ���: p<0.001 by unpaired t test. C: control, P: patient.
https://doi.org/10.1371/journal.pgen.1009339.g005
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These findings suggest that the molecular ensemble of chaperones, enzymes and modifiers
tries to compensate for the abnormal HSP47 binding, presumably by occupying the vacant
HSP47 binding sites, eventually leading to overmodification without affecting folding and
secretion.
HSP47-R222S does not induce classical ER stress or autophagy responses
Finally, we evaluated if the identified SERPINH1 variant induced an unfolded protein response
and/or signs of increased autophagic elimination in patient fibroblasts. To test for the activa-
tion of different branches of ER stress pathways, levels of BiP, XBP1-spliced, CHOP, phospho-
eIF2α and ATF6, which are induced upon accumulation of unfolded proteins, were analyzed
Fig 6. Identification of proteins interacting with gelatin sepharose. Proteins that bound tightly to gelatin sepharose were eluted with SDS sample buffer. (A-C)
Images of Western blots are shown. Cell lysate and gelatin sepharose (gel-seph) elution represent the input cell lysate that was loaded onto gelatin sepharose and the
eluted fractions from gelatin sepharose. The blot against β-tubulin is an input control. The blots with clear differences between WT and R222S HSP47 are shown.
Blots against the other proteins are shown in S9A Fig. (D) Semi-quantitative Western blotting was performed for proteins that were reported to interact with gelatin
sepharose. The protein signals of the control sample were set to 1 and compared to the patient sample. Data presented are means ± SEM and individual data points
represent four or more independently prepared cell lysate (n>4). �: p<0.05, ��: p<0.01 and ���: p<0.001 by unpaired t test. (E) Silver staining was performed for the
eluted fractions from the gelatin sepharose. The arrowhead and asterisk (�) highlight the predicted migration of BiP and HSP47, respectively. ‘-‘ indicates the eluted
fraction from gelatin sepharose mixed with TBS buffer instead of cell lysate as a blank.
https://doi.org/10.1371/journal.pgen.1009339.g006
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by Western blot. Protein levels of the general ER chaperone BiP (S10A Fig), ATF6 (S10B Fig)
and phospho-eIF2α (S10C Fig) remained unaltered in both patient and control fibroblasts.
Endogenous levels of the ER stress marker XBP1-spliced and the proapoptotic transcription
factor CHOP could not be detected, but fibroblasts did not respond differently to tunicamycin
(Tu)- or thapsigargin (Th)-induced ER stress (S10A Fig). The amount of the endogenous
autophagy marker membrane-bound LC3B-II, which is incorporated into autophagosomes,
did not differ between the patient and control (S10D Fig).
Discussion
We report a detailed pathomechanistic characterization of a novel homozygous missense vari-
ant, p.(Arg222Ser) in the HSP47 encoding gene (SERPINH1) which was identified in a child
with a severe form of OI. HSP47 is a chaperone essential for efficient folding of collagen in the
ER. We show that the substitution of the highly conserved p.Arg222 residue, which is located
in the collagen interacting surface of HSP47, by a serine residue results in reduced binding of
HSP47 to type I collagen. This pathogenic SERPINH1 variant leads to posttranslational over-
modification of type I procollagen chains, likely resulting from overcompensation by other
chaperones and molecules involved in collagen folding and biosynthesis, as demonstrated by
their significant upregulation in patients’ dermal fibroblasts, and increased binding to (dena-
tured) type I collagen. A proposed mechanism is depicted in Fig 7.
We compared our findings with those observed in all hitherto reported pathogenic human
(n = 7) and canine (n = 1) SERPINH1 variants and in the Serpinh1 knock-out (Serpinh1-/-)
mice (available data is summarized in Table 1 and missense variants are mapped to the HSP47
crystal structure in S11 Fig) and discuss their implications for type I procollagen biosynthesis
and bone formation in the context of understanding the pathomechanisms underlying the
observed OI phenotypes.
We show that HSP47 proteins harboring the p.(Arg222Ser) variant are stably expressed and
correctly localized to the ER. As such, the phenotype is not caused by reduced availability or
mislocalization of HSP47. Reduced amounts of HSP47 were nonetheless observed for the p.
(Met237Thr), p.(Leu326Pro) and p.[(Asp412�)];[p.?] variants. [15–17,21,25] For p.(Leu78Pro),
HSP47 was shown to be unstable and completely degraded via the proteasome. [16] Immuno-
fluorescent staining showed normal HSP47 localization to the ER in p.(Leu326Pro) cells
[15,25], while in p.(Met237Thr) cells, a punctate pattern was observed, with accumulation of
HSP47 in vacuolar-like compartments at the periphery of the cell. [17] The fact that on the one
hand, HSP47 levels were not reduced in our OI patient, and that on the other hand Serpinh1+/-
mice were phenotypically normal, despite marked decrease of HSP47 [14], underscores the
notion that partially decreased levels of HSP47 alone are not solely responsible for the observed
OI phenotype.
HSP47 binding prevents local or reverse unfolding of the procollagen α-chains during triple
helix formation, and prevents procollagen aggregate formation, which facilitates the transport
of procollagen to cis-Golgi. [9,10] Several arginine-containing HSP47-binding motifs with
high, medium and low binding affinity have been suggested on the surface of the procollagen
triple helix of type I and other collagens. [7,26,27] An important role for p.Arg222 in the bind-
ing of HSP47 to type I collagen was suggested by the co-crystal structure of canine HSP47 and
a homotrimeric collagen model peptide. [8] Using independent techniques, we confirmed that
the binding affinity of HSP47-R222S for type I collagen is severely diminished, although not
completely abolished. These observations indicate that the OI phenotype in our patient results
from a diminished binding of HSP47-R222S to type I procollagen, rather than from reduced
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HSP47 availability. Diminished type I collagen binding affinity was recently also demonstrated
for the previously reported p.(Leu78Pro) and p.(Leu326Pro) HSP47 variants. [28]
It is well established that monoallelic glycine substitutions and other structural defects in
COL1A1 and COL1A2 and bi-allellic pathogenic variants in CRTAP, LEPRE1 (P3H1) and
PPIB delay procollagen folding, leading to prolonged exposure of the nascent α-chains to
hydroxyl- and glycosyltransferases in the ER. [29,30] SDS-PAGE analysis on cultured fibro-
blasts of patients with these defects typically shows a slower migration pattern of overmodified
α1(I)- and α2(I)-chains. We also observed clear overmodification of the type I (pro)collagen
chains on SDS-PAGE, a finding which was confirmed by amino acid analysis and mass spec-
trometry data, which showed markedly increased hydroxylation and glycosylation of proline
and lysine residues. This is also in line with the increased thermal stability of type I collagen
observed in our patients’ fibroblasts. Despite increased posttranslational overmodification,
procollagen folding was not significantly delayed in patient fibroblasts. This suggests that
the overmodification could not be explained by prolonged exposure of the pro-α-chains to
hydroxyl- and glycosyltransferases. SDS-PAGE of dermal collagen and mass spectrometry
analysis of bone collagen also revealed increased modifications for the canine p.(Leu326Pro)
variant, including increased hydroxylation of non-crosslinking and crosslinking lysines.
[25] In addition, abnormalities in bone crosslinking were observed for the latter substitution.
The authors suggested that this could negatively influence trabecular bone formation, thus
Fig 7. Proposed mechanism of HSP47-R222S. Wild-type (WT) is depicted on the left, R222S on the right. In R222S
fibroblasts, increased levels of modifying enzymes are detected, which can bind the nascent procollagen α1(I)- and α2
(I)-chains (depicted in black and grey, respectively) and eventually result in overmodification of the respective pro-α
(I)-chains due to an increased enzyme to α-chain ratio. Following trimerisation of the pro-α-chains, HSP47-R222S
binds with lower affinity to the procollagen triple helix. The lack of triple helix stabilization by defective HSP47
binding potentially result in local unwinding of the triple helix, thereby making the individual pro-α-chains accessible
to the modifying enzymes for additional posttranslational modifications. In addition, the vacant HSP47 binding sites
can presumably be occupied by other chaperones (e.g. BiP). This will result in overmodification of pro-α-chains
without delaying the folding or secretion of type I procollagen. The overcompensation by the molecular ensemble in
combination with the fact that HSP47-R222S can still bind to type I procollagen, allows it to still function as a guide
molecule, bind to TANGO1 and direct procollagen molecules to special secretory vesicles, resulting in secretion of
overmodified type I procollagen. The incorporation of overmodified type I collagen will subsequently result in
aberrant collagen fibrillogenesis.
https://doi.org/10.1371/journal.pgen.1009339.g007
PLOS GENETICS HSP47 mutation leads to osteogenesis imperfecta
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009339 February 1, 2021 13 / 27
contributing to the OI pathology. Crosslinking studies were not performed in our patient, nor
in the other reported variants. Biochemical analysis did not reveal signs of overmodification in
p.(Leu78Pro), p.(Met237Thr) and p.[(Asp412�)];[p.?] fibroblasts. [16,17,21] The discrepancy
between these observations remains unexplained but could result from variant-specific (com-
pensatory) effects, or, alternatively, the overmodifications caused by the latter variants could
be too mild to be picked up in fibroblast culture.
In an attempt to explain the observed overmodification, we analyzed the expression and
protein levels of several chaperones and enzymes involved in folding and posttranslational
modification of procollagen in the patients’ dermal fibroblasts. Our Western blot results show
that aberrant binding of HSP47 to type I procollagen results in increased levels of FKBP65,
PDI, P4HA1, CypB, P3H1, CRTAP, P3H3, SC65, LH1 and LH3. In a gelatin sepharose pull-
down assay, we also observed a significantly increased binding capacity to denatured type I
collagen for several of these molecules (PDI, P4HA1, P3H1, CRTAP, CypB, LH1, but also
BiP). The absence of increased binding of FKBP65, despite increased protein levels, can be
explained by the weaker binding affinity between FKBP65 and collagen compared to FKBP65
and HSP47. [31] Since mutant HSP47 levels are not altered in our patient, FKBP65 preferen-
tially binds to HSP47.
These findings suggest that the observed overmodification of type I (pro)collagen in our
patient can be the result of an increased binding capability of this ‘molecular ensemble’ to type
I procollagen. Increased levels of modifying enzymes can lead to overmodification due to an
increased enzyme to α-chain ratio. In addition, the lack of triple helix stabilization by defective

















Phenotype Severe OI Severe OI Moderately severe OI Moderate OI OI embryonic lethal
HSP47 protein instability No Yes Yes Yes decreased (50%) /
HSP47 localization ER absent ER-related vesicles absent ER /
Type I collagen migration
(SDS-PAGE)
Delayed Normal Normal Normal Delayed Delayed a
COL1 overmodification Yes No ND b No Yes ND
3-hydroxylation of Pro-
986
Normal Normal ND ND Normal ND
Accumulation of COL1 ND Golgi ER-related vesicles Golgi (slightly) ER ER
ER dilatation ND ND ND ND Yes Yes
ER stress markers Normal ND ND ND upregulated upregulated
Autophagy marker Normal ND ND ND Normal upregulated
COL1 secretion Normal Slow ND ND Slow Slow
COL1 thermal stability Increased Increased ND ND ND ND
Inefficient COL1
processing
No ND ND ND Yes Yes
Bone crosslinking
alterations
ND ND ND ND Yes ND
Reported pathogenic variants that were not further explored experimentally were not included in this table.
a in the presence of ascorbate.
b ND: not determined.
https://doi.org/10.1371/journal.pgen.1009339.t001
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HSP47 binding potentially results in local unwinding of the triple helix, thereby making the
individual pro-α-chains accessible to the modifying enzymes for additional posttranslational
modifications. Furthermore, vacant HSP47 binding sites can presumably be occupied by other
chaperones (Fig 7). Together, these events lead to overcompensation by the molecular ensem-
ble, which, to the best of our knowledge, has not yet been described as a cause of overmodifica-
tion in pathogenesis of OI. Our findings potentially suggest a role for HSP47 as a regulator of
posttranslational modification. Interestingly, previous studies have indicated a role for HSP47
as a negative regulator of prolyl-4-hydroxylation [32] and LH2 [33]. Duran et al. showed that
HSP47 forms a chaperone complex with FKBP65 and BiP that regulates the occupancy and/or
the activity of LH2 on telopeptide lysine residues, in which LH2 activity is positively regulated
by FKBP65 and negatively regulated by HSP47. Fibroblasts from an OI patient harboring the
p.(Met237Thr) substitution showed increased LH2 levels, associated with a significant increase
in telopeptide lysyl hydroxylation. [33] In contrast, we observed decreased levels of LH2, but
we did not assess telopeptide modifications. The discrepancy in LH2 expression levels between
our findings and those by Duran et al. possibly reflects variant-specific outcomes. It remains
possible that the HSP47-FKBP65-BiP complex contains other ER resident chaperones and
molecules, each of which can be affected when HSP47 is defective.
In line with normal folding and secretion of procollagen, we did not observe upregulation
of ER stress markers (BiP, CHOP, XBP1-spliced, phospo-eIF2α or ATF6) in fibroblasts from
our patient, nor did we observe induction of autophagy. As such, classical ER stress and/or
autophagy pathways were not activated and most likely do not contribute to the phenotype of
our patient. In contrast, in canine p.(Leu326Pro) fibroblasts, secretion of type I and type V col-
lagen was slightly decreased and type I procollagen accumulated in the ER, leading to activa-
tion of ER stress response markers BiP and phospho-eIF2α and dilatation of ER cisternae. [25]
Accumulation of type I procollagen in the ER and enlarged ER cisternae were also observed in
fibroblasts from Serpinh1-/- mice. Serpinh1-/- mouse embryonic fibroblasts showed induction
of CHOP and splicing of XBP1 [34], and involvement of the autophagy-lysosomal pathway to
clear misfolded trimeric collagen aggregates. [35] These observations suggest that, in contrast
to our findings, the Serpinh1-/- mouse and the canine p.(Leu326Pro) HSP47 show partial intra-
cellular retention of procollagen with activation of an ER stress response potential having a
causative role in the OI pathomechanism. [25,34,36]
In summary, our study confirms that bi-allelic SERPINH1 variants result in severe OI and
illustrates that the p.(R222S) variant compromises the interaction between HSP47 and type I
procollagen, which disturbs the HSP47-mediated quality control of collagen biosynthesis and
triggers a cascade of molecular events resulting in altered type I collagen modification and sta-
bility. Although the role of overmodification in OI pathology remains unclear, we hypothesize
that the secretion of overmodified type I collagen can potentially hamper lateral fusion of colla-
gens, which can severely compromise collagen fibrillogenesis. In addition, defective crosslink-
ing could potentially impair osteoblast maturation and increase osteoclast recruitment, which
can affect bone mineralization. [37] Therefore, the incorporation of overmodified type I colla-
gen likely has a detrimental effect on collagen fibrillogenesis, bone ECM and cell populations,
thereby affecting cell-matrix interactions and signaling, and eventually contributing to the
bone fragility observed in our patient. Nevertheless, the clinical severity of classical OI does
not correlate with the extent of posttranslational overmodification, thereby indicating that the
role of overmodification in OI pathology is complex. Since patients with HSP47 defects typi-
cally present with an OI phenotype, bone is the main tissue for which manifestations are docu-
mented. Of note, some patients with HSP47 defects present with joint hypermobility and
generalized hypotonia, suggesting that also tendon/ligaments and muscle function can be
compromised. In addition, respiratory problems are observed in 5 out of 9 reported patients,
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including our patient (S1 Table). Since only a small number of patients with HSP47 defects has
been reported, it is hard to draw conclusions on extraskeletal manifestations. The observation
that bone is the most prominently affected tissue when HSP47 is defective, despite the abun-
dant expression of type I collagen in multiple tissues and the ability of HSP47 to chaperone
several types of collagen, is currently not well understood. There could be several explanations.
First, differences are observed in the number and affinity of HSP47-binding motifs for differ-
ent collagen types [7]. This indicates that not all collagen types are dependent on HSP47 in the
same way. Since the α1- and α2-chain of type I collagen harbor the highest number of HSP47
binding sites, this possibly explains why type I collagen is most affected. Second, the expression
of HSP47 might differ between different tissues and cell types, which can also add to the final
(tissue-specific) effect. Third, posttranslational modifications differ between tissues. For exam-
ple, the amount of O-glycosylation was observed to be lower in bone compared to skin and
tendon. [2,38] It appears that bone is more sensitive to overmodification since small changes
can have a huge effect. Therefore, even subtle alterations in posttranslational modification of
collagen might have more devastating effects in bone compared to other tissues. Of note, as we
used dermal fibroblasts for our experiments because of the unavailability of osteoblasts, we
cannot exclude tissue-specific differences.
Comparison of our results with those obtained in other reported pathogenic human/canine
SERPINH1 variants reveals variant-specific outcomes both on HSP47 stability and subcellular
localization and on its collagen chaperoning function, leading to different functional conse-
quences on type I procollagen, and different clinical outcomes. As such, the observed clinical
and biochemical differences most likely reflect a combination of the location and nature of the
substitution in the HSP47 structure, the resulting protein stability of mutant HSP47 and its
subcellular localization, the remaining binding affinity of mutant HSP47 to procollagen and
the ability of mutant HSP47 to interact with and/or regulate other proteins, affecting down-
stream pathways to a different extent. Although the precise mechanisms that drive bone fragil-
ity in these patients remain poorly understood, the observed alterations likely interfere with
proper collagen fibril assembly in the ECM and as such disturbed bone formation.
Materials and methods
Ethics statement
This study was approved by the Ethics Committee of Ghent University Hospital, Belgium
(number 2013/1118). Written informed consent was obtained from the parents of the affected
child.
Patient information and material
A skin biopsy was taken from the patient and blood samples were obtained from both parents.
Genomic DNA was extracted using the Gentra Puregene extraction method (Qiagen, Hilden,
Germany).
Molecular analysis
All coding exons and flanking intronic regions of OI-associated genes (COL1A1, COL1A2,
IFITM5, LEPRE1, CRTAP, PPIB, FKBP10, PLOD2, SERPINH1, SERPINF1, BMP1, TMEM38B,
WNT1, SP7 and OASIS) were PCR amplified and subsequently pooled, indexed and subjected
to Nextera XT library preparation (Illumina, San Diego, CA, USA) prior to sequencing on the
MiSeq instrument (Illumina). Data were mapped and variants were called using the CLC
Genomics Workbench (Qiagen) and subsequently annotated and analysed. [39] Confirmation
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and segregation analysis was performed by PCR amplification of the corresponding exon of
SERPINH1 (NM_001235.3) followed by bidirectional sequencing using the BigDye Termina-
tor Cycle Sequencing kit and the ABI 3730XL DNA Analyzer (Applied Biosystems, Foster
City, CA, USA). The pathogenicity of the variant was evaluated using the Alamut Visual soft-
ware (version 2.3, Interactive Biosoftware, Rouen, France) including the prediction tools SIFT,
PolyPhen2, AlignGVGD and MutationTaster and its occurrence was assessed using the
Genome Aggregation Database (gnomAD release 2.0.2) (http://gnomad.broadinstitute.org)
and the Osteogenesis Imperfecta variant database (http://oi.gene.le.ac.uk/home.php?select_
db=SERPINH1). The variant was classified according to the standards and guidelines of the
American College of Medical Genetics and Genomics. [40] The canine HSP47 crystal structure
was retrieved from the RCSB Protein Data Bank (www.rcsb.org, accession number 4AU3) and
used for variant modelling using the UCSF Chimera software (version 1.10, build 40293).
Expression analysis
Primary dermal fibroblast cultures were established from a skin biopsy and grown and main-
tained in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with 10% fetal bovine serum Good (Pan Biotech, Aiden-
bach, Germany), 1% non-essential amino acids (Gibco), 1% penicillin/streptomycin (Gibco),
1% kanamycin (Gibco) and 0.1% amphotericin B (Gibco) and incubated at 37˚C with 5% CO2.
Total RNA was extracted from fibroblast cultures in triplicate using the RNeasy kit (Qiagen)
with on-column DNase digestion, followed by cDNA synthesis using the iScript cDNA Syn-
thesis Kit (Bio-Rad Laboratories, Hercules, CA, USA) and RT-qPCR for SERPINH1 and genes
encoding proteins involved in collagen biosynthesis (primers available upon request) was per-
formed in duplicate. Data analysis was performed with the qBasePlus software (Biogazelle,
Ghent, Belgium) using reference genes HPRT1, YWHAZ and RPL13A for normalization.
Immunoblotting
Dermal fibroblasts from the patient and a healthy control were grown until confluency, incu-
bated for 4 hours in either the absence or presence of the ER stress inducers tunicamycin
(10 μg/ml) or thapsigargin (1 μM) (both Sigma-Aldrich, St. Louis, MO, USA) and were subse-
quently lysed with RIPA buffer (Sigma-Aldrich) containing protease (Roche, Basel, Switzer-
land) and phosphatase inhibitors (Sigma-Aldrich). An aliquot was subjected to SDS-PAGE
and transferred to nitrocellulose membranes, immunolabeled with primary antibodies against
HSP47 (ab54874, Abcam, Cambridge, United Kingdom), BiP (#3183, Cell Signaling Technolo-
gies (CST), Danvers, MA, USA), CHOP (#2895, CST), XBP1-spliced (647502, Biolegend, San
Diego, CA, USA) or LC3B (L7543, Sigma-Aldrich) and horseradish peroxidase-conjugated
secondary antibody (CST), and detected with chemiluminescence. For loading control, mem-
branes were stripped and reprobed with a β-tubulin antibody (ab6046, Abcam).
Immunofluorescence
Dermal fibroblasts were seeded at 3×105 cells/well in eight-well Lab-Tek chamber slides
(Thermo Scientific, Waltham, MA, USA) and grown under standard conditions as described
above. At confluency, cells were fixed with 4% (w/v) paraformaldehyde (Sigma-Aldrich), per-
meabilized with Triton X-100 (0.5% (v/v) in PBS) and blocked with bovine serum albumin
(BSA, 5% (w/v) in PBS). Cells were next incubated with primary antibodies HSP47 (ab54874,
Abcam) and PDI (ab3672, Abcam) and secondary antibodies (Alexa Fluor 488 conjugated
goat-anti-mouse (1:1500, Molecular Probes, Life Technologies, Carlsbad, CA, USA) and Alexa
Fluor 594 conjugated donkey-anti-rabbit (1:1500, Molecular Probes, Life Technologies)
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diluted in 2% BSA/PBS. Nuclei were counterstained with DAPI (4’-6’-diamidino-2-phenylino-
dole hydroxychloride, Vector Laboratories, Burlingame, CA, USA). Stained preparations were
analyzed using the Axio Observer.Z1 fluorescence microscope (Carl Zeiss Microscopy, Thorn-
wood, NY, USA). Images were captured with the Zen pro software and processed with Fiji.
[41]
Expression and purification of recombinant HSP47
Wild-type HSP47 was expressed and purified as described previously. [42] Shortly, a strep-
tagged construct containing the canine HSP47 sequence (36LSP. . . RDEL418) in a pJExpress411
vector was transformed into the BL21 (DE3) Escherichia coli strain, the protein expressed at
37˚C for 4h and purified using a Streptactin column. The protein was polished using size-
exclusion chromatography (Superdex 200) in 50 mM Hepes (pH 7.5), 150 mM NaCl, 2 mM
DTT and stored aliquoted at -80˚C. The R222S variant was introduced using a modified Quik-
change mutagenesis protocol [42] and purified as wild-type HSP47.
HSP47 melting temperature analysis
Protein melting points were determined by differential scanning fluorimetry using both the
thermal shift assay and intrinsic tryptophan fluorescence. Thermal shift assay was performed
essentially as described earlier. [43] Briefly, a 50 μl solution containing 1 mg/ml protein in 50
mM Tris, 150 mM NaCl, pH 7.5 (TBS) and 1x SYPRO-Orange (Invitrogen, Carlsbad, CA,
USA) was heated in a thermocycler (CFX98, BioRad) from 20˚C to 95˚C with an approximate
heating rate of 1˚C/min. Fluorescent readings were taken every 0.5˚C using the FRET channel
(Ex 450–490, Em 560–580) of the device. Tm was defined as the minima of the first derivative.
All data were measured in triplicates. Intrinsic tryptophan fluorescence was measured using a
Prometheus NanoDSF (NanoTemper Technologies GmbH, München, Germany) according
to the manufacturer protocol. Briefly, protein in MacIlvaine buffer (0.2 M Na2HPO4/0.1 M cit-
ric acid pH 7.5) was loaded into capillaries and the temperature was increased by 1˚C/min
from 20˚C to 95˚C. Intrinsic tryptophan fluorescence was measured at 330 nm and 350 nm
and plotted as 350/300 nm ratio. Tm was defined as the minima of the first derivative. All data
were measured in duplicates. Analysis of the data was performed using the Origin2018b
software.
Biolayer interferometry (BLI)
Measurements of the binding kinetics using biolayer interferometry was performed as
described earlier. [44]. Shortly, a foldon stabilized collagen model peptide, containing a
(GPP)5GPR(GPP)6 collagen sequence (GPR-foldon), was biotinylated and immobilized to
streptavidin-coupled biosensors (FortéBio, Fremont, CA, USA). Sensors were blocked with
10 μM biocytin and unspecific interactions reduced with multiple load/regeneration cycles
using McIlvaine buffer at pH 6 for regeneration. All interaction studies were performed in 50
mM Tris, 150 mM NaCl, pH 7.5 (TBS). All datasets were measured twice. The koff and kon
value were individually fitted in Origin 2018b using a 1:1 Langmuir binding model. KD values
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Surface Plasmon Resonance (SPR) analysis
SPR experiments were carried out using a BIAcore X instrument (GE Healthcare, Chicago, IL,
USA). Purified type I collagen from mouse tail tendon was immobilized on a CM5 sensor chip
by amide coupling. The approximate coupled protein concentration was 6 ng/mm2 (6,000
response units) of type I collagen. The experiments were performed at 20˚C in HBS-P (10 mM
Hepes, pH 7.4, containing 150 mM NaCl and 0.005% Surfactant P20) using a flow rate of
10 μl/min. All curves are the average of at least three replicates and three independent mea-
surements were performed. For the analysis of the binding affinity, the curves were fitted with
the Langmuir binding model (BIAevaluation software; GE Healthcare).
Enzyme-linked immunosorbent assay (ELISA)
For ELISA binding assays, type I collagen from rat tail (BD Bioscience, San Jose, CA, USA)
was diluted in TBS and coated at 10 μg/mL (500 ng per well) overnight at room temperature
onto 96-well plates (MaxiSorp, Nunc, Roskilde, Denmark). After washing with TBS/0.05%
Tween-20, plates were blocked for 1 h at room temperature with 5% milk powder in TBS. His-
tagged HSP47 proteins were added at concentrations ranging from 1.2 to 5,000 nM. After
washing with TBS/0.05% Tween-20, bound ligands were detected with a HRP-coupled anti-
His tag antibody (Miltenyi Biotech, Bergisch Gladbach, Germany) and visualized with tetra-
methylbenzidine as substrate. The reaction was stopped by adding 10% H2SO4, and absorption
was measured at 450 nm. The data were analyzed using Origin 2018b and fitted using a four-
parameter logistic model. [45] All measurements were performed twice and representative
curves are shown.
Biochemical collagen analyses
For steady-state (pro)collagen analyses, fibroblasts were plated in petri dishes and grown in
medium (composition as described above) supplemented with 25 μg/ml ascorbic acid for 24 h.
Next, confluent cell layers were labeled, and procollagen was harvested, precipitated, digested,
and separated as described before. [46]
Collagen thermal stability analysis
Collagen thermal stability was determined as described in [47]. This analysis was performed in
duplicate.
Circular dichroism measurements
Patient and control dermal fibroblasts were cultured in DMEM with 4.5 g/L glucose, L-gluta-
mine, and sodium pyruvate containing 10% (v/v) FBS (Atlanta Biologicals, Flowery Branch,
GA, USA), Pen Strep Glutamine (100×; Life Technology), and 5 mM Hepes in presence of
ascorbic acid phosphate (100 μg/mL; Wako Chemicals GmbH, Neuss, Germany). Type I colla-
gen was extracted from conditioned serum-free media of cultured dermal fibroblasts following
standard ammonium sulfate precipitation, followed by pepsin digestion in acetic acid and two
precipitation steps with 0.7 M NaCl in acetic acid and 2.5 M NaCl at pH7. Circular dichroism
spectra were recorded on an AVIV 202 spectropolarimeter (AVIV Biomedical, Inc., Lake-
wood, NJ) using a Peltier thermostated cell holder and a 1 mm path length rectangular quartz
cell (Starna Cells Inc., Atascadero, CA). Protein concentrations were determined by amino
acid analysis. The thermal unfolding of collagen molecules was monitored at 222 nm wave-
length at -6˚C/hour and 1˚C/min or 0.1˚C/min heating rate. The proteins were measured in
100 mM acetic acid.
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Intracellular folding rate assay
Patient and control fibroblasts were plated in 15 cm dishes and grown to confluency. Follow-
ing stimulation of procollagen biosynthesis with 50 μg/ml ascorbic acid 2-phosphate for one
day, cells were preincubated in pulse medium (Met- and Cys-free DMEM with 10% FBS and
50 μg/ml ascorbic acid 2-phosphate) without L-azidohomoalanine (AHA, Click Chemistry
Tools) at 37˚C for 30 min to deplete methionine. Pulse labeling was performed with 1 mM
AHA in pulse medium at 37˚C for 15 min, and cells were incubated in chase media (standard
DMEM with 10% FBS, cold methionine and 50 μg/ml ascorbic acid 2-phosphate) at room tem-
perature for different time intervals (i.e. 2 min, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min
and 40 min). After the chase, the cells was washed with PBS, and 1250 μL of M-PER cell lysis
buffer (Thermo Scientific) containing a final concentration of 1% NP40 (Thermo Scientific),
200 mg/mL chymotrypsin (Sigma), 80 mg/mL trypsin (Sigma), and 0.5 mg/mL DNASE I
(ROCHE) was added directly to the cells. After 30 sec incubation, the cell lysate was collected
by a cell scraper into a microcentrifuge tube and centrifuged at the highest speed by a tabletop
centrifuge at room temperature for 2 min. The supernatant was transferred to a new 2.0 mL
microcentrifuge tube and mixed with 250 μL of 1 M acetic acid containing 0.6 mg/mL pepsin
(Sigma) at room temperature for 1 hour. After pepsin digestion, 500 μL of 5 M NaCl was
added to the tube and incubated at 4˚C for overnight. Type I collagen was precipitated at the
highest speed by a tabletop centrifuge. The pellet containing type I collagen was dissolved by
43 μL of TBS and labeled with 2 μL of Click-iT Alexa Fluor 488 sDIBO Alkyne (Thermo Scien-
tific) at room temperature for an hour. This labeled solution was mixed with 15 μL of 4x Bolt™
LDS Sample Buffer without reducing agent and heat and separated on precast Bolt™ 4–12%
Bis-Tris Plus Gels with MES running buffer (Thermo Scientific). The signals from AHA-Alexa
Fluor 488 were detected by the ChemiDoc MP imaging system (BioRad) using the software
Image Lab version 4.0.1 (BioRad). The intensities of fluorescent signals were measured by
Image J. The AHA incorporated type I procollagen as a loading control was purified from cell
culture media after the overnight chase with the method as described above. To quantitate the
amount of newly synthesized AHA incorporated type I collagen at each chase time point, the
fluorescent signal of AHA incorporated type I collagen was normalized to the signal corre-
sponding to the total amount of type I collagen (with and without AHA) stained with GelCode
Blue Stain Reagent (Thermo Scientific). This assay was performed 4 times and representative
images are shown.
Secretion rate assay
Patient and control fibroblasts were grown to confluency as described in the ‘Circular dichro-
ism measurements’ section, trypsinized, and counted. Cells were adjusted to equalize cell
number across different cell types and then resuspended in serum-free medium and
recounted. Cells were preincubated in labeling medium (methionine-free Dulbecco’s modi-
fied Eagle’s medium without fetal bovine serum but with ascorbate at a final concentration
of 50 μg/ml at 37˚C with gentle shaking for at least 20 min). Cells were briefly centrifuged,
and medium was removed and replaced with 10 ml of labeling medium containing 1 mCi
[35S]methionine (American Radiolabeled Chemicals, Inc., St. Louis, MO, USA) and incu-
bated with shaking at 37˚C for 30 min. Cells were then spun out briefly and resuspended in
chase medium (standard Dulbecco’s modified Eagle’s medium with cold methionine and
ascorbate) and aliquoted for separate time points (i.e. 10 min, 20 min, 30 min, 45 min, 60
min, 90 min, 2 h, 3 h and 4 h). Cells were incubated at 37˚C with shaking, removed at each
time point, and spun out at high speed. Medium was transferred to a labeled fresh tube, and
cell pellet and medium were frozen. After thawing 1 ml of lysis buffer (1% Nonidet P-40 and
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10 mM EDTA in phosphate-buffered saline) was added to each cell pellet and mixed. Cell
lysates and medium were precipitated with ammonium sulfate (200 mg per 1 ml of volume
was added to each tube, incubated 2–3 h with shaking at 4˚C). Precipitates were centrifuged
at high speed for 20–30 min at 4˚C and the resultant pellet was resuspended in 0.5 M acetic
acid with 0.4 mg/ml pepsin. Samples were digested overnight at 4˚C with shaking. Pepsinized
collagen extracts were precipitated with 0.7 M NaCl final concentration at 4˚C and spun out
at high speed for 30 min. Pellets were resuspended in 0.5 M acetic acid and SDS-PAGE sam-
ple buffer, run on 6–8% acrylamide gels, dried, and exposed to film for autoradiography. A
similar protocol was performed in duplicate using 14C-proline and alternative time points
(i.e. 0 min, 20 min, 40 min, 60 min and 120 min).
Amino acid analyses
Acid- and base-hydrolyzed collagen was analyzed as reported previously. [48] Acid hydrolysis
was performed in triplicate and base hydrolysis once.
Collagen digestion and mass spectrometry analysis
To digest type I collagen in trypsin, lyophilized samples were resuspended in equal volume as
the pre-lyophilisate of 1M Tris-HCl pH 8.0 with 20 ng/μL trypsin and digested for 18 hours at
37˚C. Identification of peptides produced by proteolytic digest was performed on a Q-TOF
Micromass spectrometer (Waters, Billerica, MA, USA) equipped with an electrospray ioniza-
tion source. Data were collected with the MassLynx (version 4.1) data acquisition software
(Waters) and processed using Mascot Distiller (Matrix Software, London, United Kingdom).
High performance liquid chromatography was performed with nanoACQUITY (Waters) sys-
tem using a 75 μm x 100 mm 3 μm Atlantis dC18 column as the analytical column and a
180 μm x 20 mm 5 μm Symmetry C18 column as the trapping column. Chromatographic
mobile phases consisted of solvents A (0.1% formic acid and 99.9% water (v/v)) and B (0.1%
formic acid and 99.9% acetonitrile (v/v)). Peptide samples were loaded onto the trapping col-
umn and equilibrated 4 min in 99% solvent A followed by a 180 min gradient to 60% solvent
A, 40% solvent B at a constant flow rate of 0.8 μl/min. Analysis was performed in survey scan
mode. Tryptic peptides were identified from MS/MS spectra by a Mascot search against the
National Center for Biotechnology Information (NCBI) database (peptide tolerance 1.0 Da,
MS/MS tolerance 1.0 Da).
Protein level analyses by Western blotting
Patient and control dermal fibroblasts were cultured in 60 mm dishes. Cell lysates were
extracted using M-PER (Thermo Fisher Scientific) containing Halt™ Protease Inhibitor Cock-
tail, EDTA-Free (Thermo Fisher Scientific) at 4˚C. For detection of ATP6, the culture medium
was replaced with and without 50 mM DTT after the cells grew to over 80% confluency. After
incubation for 90 minutes, the cells were washed twice with PBS and lysates were extracted
using RIPA buffer (Thermo Fisher Scientific) containing Halt™ Protease Inhibitor Cocktail,
EDTA-Free (Thermo Fisher Scientific) at 4˚C. After centrifugation, soluble proteins in the
extract were mixed with SDS sample buffer with reducing agents. These protein solutions were
separated on Bolt 4–12% Bis-Tris Plus Gels (Thermo Fisher Scientific) then transferred to
PVDF membranes and Western blots were performed using antibodies listed in S3 Table.
Blots were developed with HRP enhanced SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific) and detected by ChemiDoc MP imaging system (BioRad) using the
software Image Lab version 5.2 (BioRad). The intensities of protein signals were measured by
Image J. [41]
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Gelatin sepharose pulldown assay using cell lysate
Patient and control dermal fibroblasts were cultured in 150 mm dishes and cell lysates were
prepared with M-PER as described above. Six ml of cell lysates in which the total protein con-
centration was normalized to 1.0 OD at 280 nm measured in a Cary 4 Series UV-Vis spectro-
photometer (Agilent Technologies, Santa Clara, CA, USA) were incubated with 1.5 ml of
gelatin Sepharose 4B (GE Healthcare) for 2 h at 4˚C. After washing twice with 10 ml TBS
buffer followed by a wash with 25 mM Tris buffer, pH 7.4, containing 1 M NaCl and addition-
ally twice with TBS buffer, sepharose beads were eluted with 2X SDS-PAGE sample buffer con-
taining β-mercaptoethanol by heating to 95˚C for 5 min. The eluted proteins were separated
by SDS-PAGE followed by transfer to PVDF membrane and Western blotting and analyses
were performed as described earlier. Gels were also stained with SilverXpress Silver Staining
Kit (Thermo Fisher Scientific).
Statistical analyses
For comparisons between patient and control, we performed unpaired t test to determine
whether differences were significant using ORIGIN Pro ver. 9.1 (OriginLab Corp., Northamp-
ton, MA, USA) or GraphPad Prism software (v5; GraphPad Software, LaJolla, CA, USA). A P
value of less than 0.05 was considered statistically significant.
Supporting information
S1 Fig. Melting temperature analysis. Differential Scanning Fluorimetry based on intrinsic
tryptophan fluorescence (A) and SYPRO Orange binding (B) showed a similar melting point
for both wild-type (WT) (59.35˚C and 54.50˚C) and R222S (57.48˚C and 54.00˚C) protein,
indicating that the variant does not cause structural instability.
(TIFF)
S2 Fig. Intracellular folding rate assay of type I collagen produced by dermal fibroblast cul-
tures. (A) Quantification of the folding rate of type I collagen (n = 4) presented in Fig 4B of
the manuscript. To quantitate the amount of newly synthesized AHA incorporated type I col-
lagen at each chase time point, the fluorescent signal of AHA incorporated type I collagen was
normalized to the signal corresponding to the total amount of type I collagen (with and with-
out AHA) stained with GelCode Blue Stain Reagent (Thermo Scientific). The signal at 40 min-
utes of AHA incorporated type I collagen was set to 1 to compare with that of the other chase
time points. (B) Calculation of the area under the curve (AUC). Each dot represents a separate
experiment. Results are shown as mean ± SEM. ns: not significant by unpaired t test. Although
the folding appears slightly faster in patient versus control fibroblast, no significant difference
could be observed. C: control, P: patient.
(TIFF)
S3 Fig. Secretion rate assay of type I collagen produced by dermal fibroblast cultures. (A)
Quantification of the secretion rate of type I collagen presented in Fig 4C of the manuscript.
(B) Additional secretion rate assay of type I collagen performed using an alternative experi-
mental setup. (C) Quantification of the secretion rate of type I collagen in the medium using
the alternative experimental setup (n = 2). Data presented are means ± SEM. Both setups show
a near-normal secretion rate for patient compared to control. C: control, P: patient.
(TIFF)
S4 Fig. Melting curve analysis of type I collagen. Circular dichroism measurements of type I
collagen extracted from control (black) and patient (pink) fibroblasts performed at a heating
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rate of 1˚C/min. C: control, P: patient.
(TIFF)
S5 Fig. Amino acid analysis of type I collagen extracted from control and patient dermal
fibroblasts. (A) Amino acid analysis of type I collagen after acid hydrolysis shows apparently
normal levels of prolyl 4-hydroxylation and slightly increased levels of prolyl 3-hydroxylation
in patient samples (insert). 3-Hyp: 3-hydroxyproline, 4-Hyp: 4-hydroxyproline, Pro: unmodi-
fied proline. (B) Amino acid analysis of type I collagen after acid hydrolysis shows increased
levels (30%) of lysyl hydroxylation in patient samples. Hyl: hydroxylysine, Lys: unmodified
lysine. (C) Amino acid analysis of type I collagen after base hydrolysis shows significantly
increased glycosylation in patient samples. Glucosyl-galactosyl hydroxylysine content is
increased by approximately 50% in patient samples, while no change in galactosyl hydroxyly-
sine is observed. GGH: glucosyl-galactosyl hydroxylysine standard in blue, GH: galactosyl
hydroxylysine standard in green. (D) Quantification of proline and lysine modifications after
acid hydrolysis show significantly increased 3-Hyp, 4-Hyp and Hyl levels in patient versus
control samples. Data presented are means ± SEM. �: p<0.05, ��: p<0.01, ���: p<0.001,
unpaired t test. (E) Calculation of the percentage and increase in modification. The percentage
was calculated as the number of hydroxylated lysine/proline residues divided by the total num-
ber of lysine/proline residues. Mean is represented with SEM between brackets. C: control, P:
patient.
(TIFF)
S6 Fig. Mass spectrometry data of trypsin digested type I collagen. Type I collagen was
extracted from conditioned culture media of control and patient dermal fibroblasts. (A,B)
3-Hydroxylation of proline residues is normal at the A1 site (P986) (A) and increased at the
A3 site (P707) (B) of the type I collagen α1-chain. (C-D) Additional sugar attachment is
observed at lysyl hydroxylation sites at residues K174 (C) and K531 (D) of the type I collagen
α1-chain from patient cells. (E) Increased lysyl hydroxylation at residue K756 of the type I col-
lagen α1-chain from patient cells. The peptide sequence is shown above the mass spectra and
the examined residue is depicted in red. C: control, P: patient.
(TIFF)
S7 Fig. Western blots against proteins of the molecular ensemble involved in collagen bio-
synthesis using cell lysates. The cell lysate extracted from patient and control dermal fibro-
blast cultures were electrophoresed on a Bolt 4–12% Bis-Tris Plus Gel followed by transfer to
PVDF and Western blotting. Antibodies used to the blotting are listed in S3 Table. The arrow-
head indicates the migration corresponding to the molecular weight of the protein, which was
used for further quantitative analysis. C: control, P: patient.
(TIFF)
S8 Fig. Expression analysis of transcripts encoding proteins of the molecular ensemble
involved in collagen biosynthesis. RT-qPCR was performed to assess expression levels. Pro-
tein names are indicated and the corresponding HUGO-approved gene name is included
between brackets. Data presented are means ± SEM and individual data points represent inde-
pendently prepared total RNA. �: p<0.05, ��: p<0.01, ���: p<0.001 and ns: not significant by
unpaired t test. C: control, P: patient.
(TIFF)
S9 Fig. Western blots against proteins of the molecular ensemble involved in collagen bio-
synthesis that bind gelatin. Western blots for the gelatin sepharose elution fraction of pro-
teins that (A) bind to gelatin and (B) do not bind gelatin. The cell lysate extracted from
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control and patient dermal fibroblasts and the eluted fractions from gelatin sepharose are
depicted. The red color on the gel bands indicates that a membrane was overexposed and the
signals were saturated. The asterisk (�) in the LH3 blot highlights the predicted migration of
LH3. The additional, non-specific bands in the input lysate of the LH3 blot, compared to S7
Fig, could be due to much higher protein concentration of cell lysate for the gelatin sepharose
binding experiments. Antibodies used for the blots are listed in S3 Table. ‘-‘ indicates the
eluted fractions are from gelatin sepharose mixed with TBS buffer instead of cell lysate as a
blank. C: control, P: patient.
(TIFF)
S10 Fig. Evaluation of ER stress and autophagy signatures in dermal fibroblasts. (A) Cells
were treated with tunicamycin (+Tu), thapsigargin (+Th) or left untreated (-) as indicated and
evaluated for the presence of BiP, XBP1 spliced and CHOP. (B) Cells were either treated with
DTT (+) or left untreated (-) as indicated. ATF6 (N) and ATF6 (C) indicate the predicted size
of native full length and cleaved form by ER stress, respectively. ATF6 (C) is overlapping with
a non-specific protein. The black line spacing denotes irrelevant lanes that were eliminated
from the image. (C) Endogenous levels of eIF2α and phospho-eIF2α were evaluated. (D)
Endogenous levels of the autophagy marker LC3 were evaluated. LC3-I and LC3-II represent
the cytosolic form and the autophagosome-bound form of LC3, respectively. β-tubulin was
used as loading control. C: control, P: patient.
(TIFF)
S11 Fig. Mapping of the amino acid residues with currently identified missense variants in
HSP47. Crystal structure of the HSP47-collagen interaction with the collagen trimer depicted
centrally, surrounded by two HSP47 molecules depicted in light and dark grey. Missense vari-
ants identified in humans and dog (with asterisk) are indicated in different colors on the
HSP47 crystal structure. While residues L50, L78, L326 (canine, with asterisk) and R405 are
located further away from the collagen interaction surface, R222 (present study) and M237 are
located close to the interaction surface.
(TIFF)
S1 Table. Clinical summary of individuals with pathogenic SERPINH1 variants identified
so far. NA: not assessed, 1 personal communication with the authors.
(XLSX)
S2 Table. In silico predictions and reported allele frequency for the identified p.(Arg222-
Ser) substitution.
(XLSX)
S3 Table. Antibodies used for Western blot analyses.
(XLSX)
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